Disc Medicine, Inc.
IRONHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients. The company carries a $2.91B market cap, placing it firmly in the mid-cap category. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Market Cap
$2.91B
Beta
2.07
P/E (TTM)
—
P/E (Fwd)
-10.04
EPS (TTM)
$-6.89
EPS (Fwd)
$-7.59
ROE
-35.8%
ROA
-22.7%
Cash
$730.2M
Total Debt
$31.1M
Free CF
-$121.4M
52W Change
31.8%
Annual Financials
Cash vs Debt
Disc Medicine, Inc. holds $730.2M in cash against $31.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$121.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -35.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.07 means IRON is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, IRON has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Disc Medicine, Inc.'s trajectory.